Pyruvate kinase M2 and prednisolone resistance in acute lymphoblastic leukemia

Haematologica

Volumn 94, Issue 9, 2009, Pages 1322-1324

  Hulleman, Esther ^a   Broekhuis, Mathilde J C ^a   Pieters, Rob ^a   Den Boer, Monique L ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Childhood ALL; Glycolysis; Perdnisolone; Pyruvate kinase; Resistance

Indexed keywords

GLUCOCORTICOID; GLUCOSE; ISOENZYME; PREDNISOLONE; PYRUVATE KINASE; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW; DRUG MECHANISM; EVENT FREE SURVIVAL; GLUCOSE METABOLISM; GLYCOLYSIS; HUMAN; LETTER; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT FAILURE; UPREGULATION;

DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, LEUKEMIC; GLUCOCORTICOIDS; HUMANS; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE; PYRUVATE KINASE;

EID: 70349149448     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.011437     Document Type: Letter

References (11)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178
2. Pieters R, Klumper E, Kaspers GJ, Veerman AJ. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Oncol Hematol 1997;25:11-26. (Pubitemid 27138046)
3. Kaspers GJ, Pieters R, Van Zantwijk CH, Van Wering ER, Van Der Does-Van den Berg A, Veerman AJ. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 1998;92:259-266 (Pubitemid 28303201)
4. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Gobel U, Körholz D, et al. Patient stratification based on prednisolone- vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:3262-3268 (Pubitemid 46606259)
5. Hulleman E, Kazemier KM, Holleman A, Vanderweele DJ, Rudin CM, Broekhuis MJ, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009;113:2014-2021
6. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006;66:8927-8930
7. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230-233
8. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MW, Heyenbrok MW, et al. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990;76:2327-2336
9. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 2005;15:300-308 (Pubitemid 41058775)
10. Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005;44:9417-9429
11. Koss K, Harrison RF, Gregory J, Darnton SJ, Anderson MR, Jankwski JA. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. J Clin Pathol 2004;57:1156-1159 (Pubitemid 39486520)